Health Plan of San Mateo
Healthy is for everyone

801 Gateway Boulevard, Suite 100
South San Francisco, CA 94080
tel 650.616.0050
fax 650.616.0060
tty 800.735.2929 or dial 7-1-1
www.hpsm.org

July 29, 2026

Changes to Prior Authorization Required List Effective 9/1/2026

Dear provider,

Here are changes to the Health Plan of San Mateo's (HPSM's) prior authorization required list. Find the current list here: **https://www.hpsm.org/provider/authorizations**

130 codes were added to the prior authorization required list:

CPT Code	Description
23472	Arthroplasty, glenohumeral joint; total shoulder (glenoid and proximal humeral replacement)
0402T	Collagen cross-linking of cornea, including removal of the corneal epithelium, when performed, and intraoperative pachymetry, when performed
0552	Routine home care (service intensity add-on rate)
0607U	Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 31 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations
0608U	Reproductive medicine (endometrial microbiome assessment), real-time PCR analysis for 10 bacterial DNA targets from endometrial biopsy, reported with quantified levels of bacterial presence and targeted treatment recommendations (Do not report 0608U in conjunction with 0607U)
0609U	Oncology (prostate), immunoassay for total prostate-specific antigen (PSA) and free PSA, serum or plasma, combined with clinical features, algorithm reported as a probability score for clinically significant prostate cancer
0610U	Infectious disease (antimicrobial susceptibility), phenotypic antimicrobial susceptibility testing of positive blood culture using microfluidic sensor technology to quantify bacterial growth response to multiple antibiotic types, reporting categorical susceptibility (susceptible, susceptible dose dependent, intermediate, resistant), minimum inhibitory concentration, and interpretive comments
0611U	Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result (For additional PLA code with identical clinical descriptor, see 0612U. See Appendix O or the most current listing on the AMA CPT website to determine appropriate code assignment)
0612U	Oncology (liver), analysis of over 1,000 methylated regions, cell-free DNA from plasma, algorithm reported as a quantitative result

0613U	Oncology (urothelial carcinoma), DNA methylation and mutation analysis of 6 biomarkers (TWIST1, OTX1, ONECUT2, FGFR3, HRAS, TERT promoter region), methylation-specific PCR and targeted next-generation sequencing, urine, algorithm reported as a probability index for bladder cancer and upper tract urothelial carcinoma
0614U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 4 enzyme complexes by stained blue native polyacrylamide gel electrophoresis (PAGE), frozen tissue (muscle, liver, heart, cultured skin fibroblasts), diagnostic qualitative result
0615U	Borrelia burgdorferi (Lyme disease), antibody detection of 26 recombinant protein groups, by immunoassay, IgM
0616U	Neurology (dementia), DNA methylation analysis of more than 30,000 sites, whole blood, algorithm reported as positive or negative risk
0617U	Cardiovascular (atherosclerotic cardiovascular disease [ASCVD]), DNA methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk
0618U	Psychiatry (bipolar disorder), DNA methylation analysis of more than 10,000 sites, whole blood, algorithm reported as positive or negative risk
0619U	Pulmonary (chronic obstructive pulmonary disease [COPD]), DNA methylation analysis of more than 18,000 sites, whole blood, algorithm reported as positive or negative risk
0620U	Oncology (hepatocellular carcinoma), DNA methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk
0621U	Infectious disease (Lyme borreliosis), DNA methylation analysis of more than 10,000 sites, whole blood, algorithm reported as positive or negative risk
0622U	Psychiatry (major depressive disorder), DNA methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk
0623U	Autoimmune (multiple sclerosis), DNA methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk
0624U	Hepatology (nonalcoholic steatohepatitis [NASH]), DNA methylation analysis of 5,000 sites, whole blood, algorithm reported as positive or negative risk
0625U	Endocrinology (osteoporosis), DNA methylation analysis of more than 5,000 sites, whole blood, algorithm reported as positive or negative risk
0626U	Neurology (Parkinson disease), DNA methylation analysis of more than 20,000 sites, whole blood, algorithm reported as positive or negative risk
0627U	Psychiatry (schizophrenia), DNA methylation analysis of more than 15,000 sites, whole blood, algorithm reported as positive or negative risk
0628U	Nephrology (kidney disease-related genetic conditions), genomic analysis, renal disease panel, saliva, DNA, next-generation sequencing of 449 genes, reported as pathogenic or likely pathogenic variants of uncertain significance or risk alleles
0629U	Infectious disease (tuberculosis), DNA, analysis of 1 target by PCR with clustered regularly interspaced short palindromic repeat (CRISPR)-based probe detection, plasma or serum, qualitative report as detected or not detected
0630U	Oncology (breast), mRNA, gene expression profiling by microarray of 80 genes (80 content and 465 housekeeping), utilizing formalin-fixed paraffin-embedded tissue (FFPE), algorithm reported as an index that is diagnostic of a molecular subtype (luminal, basal, Her2)
0631U	Oncology (solid tumor), DNA, sequence analysis of 15 genes including BRCA1 and BRCA2 for identification of clonal hematopoiesis, blood, reported as tumor-derived or nontumor-derived

0632U	Red blood cell antigen (fetal RhD gene analysis), multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), plasma from pregnant individuals known to be RhD negative, reported as detected or not detected (Do not report 0632U in conjunction with 0488U)
0633U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA (cfDNA), next-generation sequencing (NGS) analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants and to determine fetal inheritance of maternal mutation, using maternal blood sample, algorithm reported as a fetal risk score
0634U	Oncology (breast cancer), cell-free DNA (cfDNA), evaluation of 11 ESR1 variants (E380Q, S463P, L536R, Y537C, Y537N, Y537S, D538G, V422del, L536H, L536P, Y537D) using droplet digital PCR (ddPCR), plasma, reported as positive or negative
0635U	Autoimmune (atopic dermatitis), mRNA, next-generation sequencing (NGS), gene expression profiling of 487 genes, noninvasive skin-surface scraping, algorithm reported as likelihood of response to therapy
0636U	Babesia (Babesiosis), antibody detection of 20 recombinant protein groups, by immunoassay, IgG
0637U	Babesia (Babesiosis), antibody detection of 20 recombinant protein groups, by immunoassay, IgM
0638U	Bartonella (Bartonellosis), antibody detection of 32 recombinant protein groups, by immunoassay, IgG
0639U	Bartonella (Bartonellosis), antibody detection of 32 recombinant protein groups, by immunoassay, IgM
0640U	Oncology (leptomeningeal metastases), tumor cell selection, identification, detection and enumeration based on differential CD318(CDCP1), SUSD2, CD340(erbB2/HER2), HGFR/cMET, FOLR1, EGFR, N cadherin, MUC1, EpCAM, and TROP2 antibody biomarkers, cerebrospinal fluid, reported as detection and quantification of tumor cells
0641U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), using formalin-fixed paraffin-embedded (FFPE) tissue and blood samples, initial (baseline) assessment
0642U	Oncology (minimal residual disease [MRD]), tumor DNA, next-generation sequencing (NGS), whole blood, comparison to previously performed analyses, reported as trend in circulating tumor DNA (ctDNA) level
0643U	Oncology (genitourinary cancer), cell-free circulating tumor DNA (ctDNA), 200 genes, next-generation sequencing (NGS), interrogation for single-nucleotide variants (SNVs), insertions/deletions, gene rearrangements, copy number alterations, and tumor mutation burden, using urine, identify and report mutations with clinical actionability
0644U	Oncology (leukemia), minimal residual disease (MRD) detection for rearrangements, blood or bone marrow, personalized assay design and baseline quantification
0645U	Oncology (leukemia), minimal residual disease (MRD) detection for rearrangements, based on digital PCR, blood or bone marrow, reported as not detected or detected with estimated abundance
0646U	Oncology (molecular residual disease), whole genome sequence analysis, cell-free DNA, whole blood, and formalin-fixed paraffin-embedded (FFPE) tumor tissue DNA, baseline assessment

0647U	Oncology (molecular residual disease), whole genome sequence analysis, cell-free DNA (cfDNA), whole blood, assessment utilizing patient-specific tumor information, reported as negative or percent circulating tumor DNA (ctDNA)
0648U	Oncology (solid tumor), targeted genomic sequencing analysis, to detect deletions, insertions, and substitutions in 42 genes, copy number amplifications in 10 genes, and fusions and splice variants in 18 driver genes from DNA and RNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue
0649U	Neurology (Alzheimer disease), DNA, targeted next-generation sequencing (NGS) of AD-1 and AD-2 target regions, whole blood, prognostic algorithmic analysis, reported as categorization of cognitive status
0650	Routine home care (high rate)
0650U	Drug metabolism (adverse drug reactions and drug response), genotyping of 9 genes (ie, CYP2D6, CYP2C19, G6PD, SLCO1B1, HLA-B*58:01, NAT2, CYP2C9, VKORC1, ABCG2), reported as metabolizer status and transporter function
0651U	Oncology (hereditary cancer), genomic DNA, 55 hereditary cancer pre-dispositioned genes, next-generation sequencing (NGS) and digital multiplex ligation-dependent probe amplification for variants, small indels (<40 base pairs), using saliva, whole blood, or nail clipping, interpretive clinical report with variant classification
0652	Continuous home care
0652U	Drug metabolism (adverse drug reactions), DNA analysis of 13 genes by targeted genotyping, using saliva or buccal swab, reported as diplotype and metabolizer status
0653U	Nephrology (inherited kidney disorders), DNA, analysis of approximately 700 genes associated with inherited kidney diseases by exome sequencing, using whole blood, saliva, or nail clipping, reported as an interpretive clinical report classifying pathogenic and likely pathogenic variants
0654U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 1 enzyme complex by western blot analysis, using cultured skin fibroblasts, diagnostic qualitative result
0655	Inpatient respite care
0655U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 1 enzyme complex by spectrophotometric kinetic assay, using cultured skin fibroblasts, diagnostic quantitative result
0656	General inpatient care (no respite)/hospice general care
0656U	Inborn error of metabolism (primary mitochondrial disease), mitochondrial analysis of 1 enzyme complex by radioactive activity assay, using cultured skin fibroblasts, diagnostic quantitative result
0657	Physician services
0657U	Rare diseases (constitutional/heritable disorders), rapid whole genome sequence analysis of comparator nuclear and mitochondrial DNA by next-generation sequencing (NGS), using blood or buccal sample, relevant variants reported with proband results (Use 0657U in conjunction with 0658U)

0658U	Rare diseases (constitutional/heritable disorders), rapid whole genome sequence analysis of nuclear and mitochondrial DNA by next-generation sequencing (NGS) for single-nucleotide variants (SNVs), insertions/deletions, copy number variants, uniparental disomy, and repeat expansions, using blood or buccal sample, identification and categorization of genetic variants (Use 0658U in conjunction with 0657U)
0659	Routine home care (low rate)
0659U	Rare diseases (constitutional/heritable disorders), ultrarapid whole genome sequence analysis of nuclear and mitochondrial DNA by next-generation sequencing (NGS) for single-nucleotide variants (SNVs), insertions/deletions, copy number variants, uniparental disomy, and repeat expansions, using blood or buccal sample, identification and categorization of genetic variants
0660U	Human papillomavirus (HPV), genotypes 18, 31, 33, and 35, cell-free DNA (cfDNA), whole blood, multiplex digital droplet PCR (ddPCR), quantitative
0661U	Human papillomavirus (HPV), genotype 16, cell-free DNA (cfDNA), whole blood, digital droplet PCR (ddPCR), quantitative
0662U	Transplantation medicine (kidney allograft rejection), mRNA, gene-expression profiling by real-time quantitative PCR of 12 genes (11 content and 1 housekeeping), urine, algorithm reported as a rejection risk score
0663U	Obstetrics (fetal platelet antigen noninvasive prenatal test [NIPT]), cell-free DNA (cfDNA) sequence analysis for detection of fetal presence or absence of 1 human platelet antigen or more (HPA-1a, HPA-1b, HPA-3a, HPA-5b, and others) when performed, reported as maternal/fetal incompatibility detected or not detected per selected antigen
0664U	Transplantation medicine (kidney allograft failure), RNA expression transcriptome by next-generation sequencing (NGS), profiling of 13 genes, post-transplant peripheral blood, algorithm reported as a risk score for predicting progressive fibrosis in the kidney allograft
0665U	Hepatology (metabolic dysfunction-associated steatohepatitis [MASH]), enzyme-linked immunosorbent assay (ELISA) for YKL40 and quantitative reverse transcription polymerase chain reaction (RT-qPCR) for miR-34a-5p, serum, algorithm reported as a single score for MASH activity and fibrosis
0666U	Infectious disease (wound infection), DNA, multiplex real-time PCR, wound swab, detection of 27 microbial targets and 28 antibiotic resistance targets, reported as semiquantitative for bacterial and fungal targets, and qualitative for viral- and antibiotic-resistance targets
0667U	Inborn error of metabolism (primary mitochondrial disease), determination of fibroblast growth factor 21 (FGF21) concentration by enzyme-linked immunosorbent assay (ELISA), serum or plasma, diagnostic quantitative result
0668U	Oncology (pancreas), DNA, genome sequence with 5-hydroxymethylcytosine (5hmC) enrichment and glycan biomarker analysis, whole blood or plasma, algorithm reported as cancer detected or not detected
0669U	Infectious disease (Bartonella species, Borrelia species, and Babesia species), multiplex digital PCR for detection of DNA at the genus level for each species, blood, qualitative reporting of presence or absence of each pathogen at the genus level

0670U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis combination of short and long reads for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat (STR) genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variant, proband and comparator (Do not report 0670U in conjunction with 81425, 81426, 0212U, 0213U, 0671U)
0671U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis combination of short and long reads for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat (STR) genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variant, proband and 2 comparators (Do not report 0671U in conjunction with 81425, 81426, 0212U, 0213U, 0670U)
0672U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat (STR) gene expansions, and variants in nonuniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband and comparator (Do not report 0672U in conjunction with 81415, 81416, 0214U, 0215U, 0673U)
0673U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat (STR) gene expansions, and variants in nonuniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband and 2 comparators (Do not report 0673U in conjunction with 81415, 81416, 81425, 81426, 0213U, 0214U, 0215U, 0567U, 0672U)
0674U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, insertions/deletions, copy number variants, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, short tandem repeat (STR) gene expansions, blood, saliva, or genomic DNA, identification and categorization of genetic variants, proband and comparator (Do not report 0674U in conjunction with 81425, 81426, 0212U, 0213U, 0214U, 0215U, 0567U, 0675U)
0675U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, insertions/deletions, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, short tandem repeat (STR) gene expansions, blood, saliva, or genomic DNA, identification and categorization of genetic variants proband and 2 comparators (Do not report 0675U in conjunction with 81425, 81426, 0212U, 0213U, 0214U, 0215U, 0567U, 0674U)
0676U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions

	and maternal cell contamination, fetal sample, identification and categorization of genetic variants, proband and maternal comparator
0677U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions and maternal cell contamination, fetal sample, identification and categorization of genetic variants, proband and 2 comparators
0678U	Oncology (hereditary cancer), genome sequence for 117 genes (single-nucleotide variants, deletions/insertions, and characterized intronic variants), copy number variants, duplications/deletions, mobile element insertions and inversions, blood, saliva, cultured skin fibroblasts (skin biopsy) or extracted genomic DNA, diagnostic, identification and categorization of genetic variants
0679U	Oncology (hereditary hematologic cancer), genomic DNA, whole genome sequence (single-nucleotide variants, deletions/insertions, and characterized intronic variants), copy number variants, duplications/deletions, mobile element insertions and inversions, analysis of over 105 genes, genomic DNA isolated from blood, saliva, cultured skin fibroblasts (skin biopsy), identification and categorization of genetic variants
0680U	Tobacco use, DNA analysis of 1 methylation marker (cg05575921 [AHRR]),methylation-sensitive digital PCR, whole blood, algorithm reported as quantitative percentage methylation and estimated average cigarette use per day
0681U	Tobacco use, DNA analysis of 2 methylation markers (1 content: cg05575921 [AHRR] and 1 normalizing: cg08141395), methylation-sensitive digital PCR, saliva, algorithm reported as quantitative percent methylation and estimated average cigarette use per day
0682U	Oncology (lung cancer), DNA analysis of 1 methylation marker (cg05575921), methylation-sensitive digital PCR, whole blood, algorithm results reported as the 20-year-hazard ratio for lung cancer
0683U	Oncology (lung cancer), DNA analysis of 2 methylation markers (1 content: cg05575921 and 1 normalizing: cg08141395), methylation-sensitive digital PCR, saliva, algorithm results reported as the 20-year-hazard ratio for lung cancer
0684U	Alcohol use disorder, DNA analysis of 4 methylation markers (cg02583484, cg04987734, cg09935388, cg04583842), methylation-sensitive digital PCR, whole blood, algorithm reported as a summed T-score
0685U	Alcohol use disorder, DNA analysis of 5 methylation markers (4 content: cg02583484, cg04987734, cg09935388, cg04583842, and 1 normalizing: cg08141395), methylation-sensitive digital PCR, whole blood or saliva, algorithm reported as a summed T-score
0686U	Oncology (prostate), mRNA, next-generation sequencing (NGS) gene expression profiling of 22 genes, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score
0687U	Comparative analysis using short tandem repeat (STR) markers, patient and comparative specimen, DNA, buccal swab and tissue, reported match or mismatch
0688U	Oncology (colorectal cancer), analysis of minimal residual disease (MRD), next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis in whole blood and tumor for baseline assessment to evaluate current MRD status and for comparisons to subsequent MRD assessments

0689U	Oncology (colorectal cancer), analysis of minimal residual disease (MRD) using patient-specific assays, reported as amount of circulating tumor DNA (ctDNA) detection and trend over time
0690U	Transplantation medicine (allograft rejection), quantification of donor-derived cell-free DNA (cfDNA) using digital PCR analysis of 45 single-nucleotide polymorphisms, plasma, reported as quantity of donor-derived cfDNA in plasma to determine the probability of allograft rejection
0691U	Carrier screening (cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia, and Duchenne muscular dystrophy), genomic sequence analysis panel, 6 genes (CFTR, SMN1, HBB, HBA1, HBA2, DMD) (Do not report 0691U in conjunction with 81443)
0692U	Cardiology (peripheral artery disease [PAD]), analysis of 3 proteins (midkine, angiopoietin-1, and kidney injury molecule-1 [KIM-1]), immunoassay, plasma, algorithm reported as a risk score for obstructive PAD
0693U	Oncology (head and neck), circulating tumor DNA (ctDNA), tumor-informed next-generation sequencing (NGS) analysis for 699 genes of patient-specific somatic variants identified from primary tumor tissue, postoperative lymphatic exudate specimen, algorithm reported as presence or absence of ctDNA
0694U	Oncology (monoclonal gammopathy), immunoprecipitation and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, identification of intact monoclonal immunoglobulin isotypes (IgG, IgA, IgM, kappa, lambda), and M-protein concentrations in conjunction with turbidimetry, blood, semiquantitative
0695U	Oncology (central nervous system), low-pass whole genome sequence analysis of cerebrospinal fluid, interrogation for chromosome arm-level and focal losses and gains
0696U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, RNA analysis, 350 or more genes for RNA alterations (eg, gene rearrangements and splice isoforms)
0697U	Obesity, DNA genotyping, analysis of up to 41 genes, buccal swab or blood specimen, patient biometrics, risk-score algorithm to identify a predisposition to up to 4 phenotypes, reported as likelihood to benefit from therapeutics
0698U	Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), immunoassay, serum or plasma, individual components reported with the overall result of positive or negative based on threshold comparison
1044T	Harvest of full-thickness skin for autologous heterogeneous skin-construct graft, including direct closure of donor site; first 5 sq cm or less
1045T	Harvest of full-thickness skin for autologous heterogeneous skin-construct graft, including direct closure of donor site; each additional 5 sq cm, or part thereof (List separately in addition to code for primary procedure)
1046T	Autologous heterogeneous skin-construct graft application, trunk, arms, legs; first 50 sq cm or less, or 0.5% of body area of infants and children
1047T	Autologous heterogeneous skin-construct graft application, trunk, arms, legs; each additional 50 sq cm, or each additional 0.5% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)

1048T	Autologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 50 sq cm or less, or 0.5% of body area of infants and children
1049T	Autologous heterogeneous skin-construct graft application, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 50 sq cm, or each additional 0.5% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)
B4105	In-line cartridge containing digestive enzyme[s] for enteral feeding, each
C8014	Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, including use of a suction enabled ureteral access sheath, with irrigation (if performed)
J0485	Injection, belatacept, 1 mg
J0528	Fosfomycin Disodium (Contepo)
J1289	Narsoplimab (Yartemlea®)
J1577	Immune Globulin (Qivigy)
J2361	Depemokimab-ulaa (Exdensur)
J2789	Riboflavin 5'-phosphate Ophthalmic Solution (Epioxa® and Epioxa® HD)
J3386	INJECTION, ETUVETIDIGENE AUTOTEMCEL, PER TREATMENT
J3405	Onasemnogene abeparvovec-brve (Itvisma)
J9053	INJECTION, BELANTAMAB MAFODOTIN-BLMF, 0.1 MG
Q5098	INJ, USTEKINUMAB-SRLF (IMULDOSA), 1 MG
Q5100	INJ, USTEKINUMAB-KFCE (YESINTEK), 1 MG
Q5117	INJ, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG
Q5148	INJ, FILGRASTIM-TXID, BIOSIMILAR, (NYPOZI), 1 MICROGRAM
Q5159	INJ, DENOSUMAB-DSSB, BIOSIMILAR, (OSPOMYV/XBRYK), 1 MG
Q5161	INJ, DENOSUMAB-KYQQ, BIOSIMILAR, (AUKELSO/BOSAYA), 1 MG
Q5165	INJ, DENOSUMAB-KYQQ, BIOSIMILAR, (OZILTUS), 1 MG
Q5166	INJ, DENOSUMAB-KYQQ, BIOSIMILAR, (OSVYRTI/JUBEREQ), 1 MG
Q5169	INJ, PEGFILGRASTIM-UNNE (ARMLUPEG), BIOSIMILAR, 0.5 MG
Q5170	Aflibercept-boav (Eydenzelt)
Q5171	INJ, DENOSUMAB-KYQQ, BIOSIMILAR, (BONCRESA), 1 MG
Q9997	INJ, USTEKINUMAB-TTWE (PYZCHIVA), IV, 1 MG

60 codes were removed from the list for no longer requiring prior authorization:

CPT Code	Description
37799	VASCULAR SURGERY PROCEDURE
55708	Biopsy, prostate, transrectal, ultrasound-guided (ie, sextant) with MRI-fusion-guidance, first targeted lesion
55709	Biopsy, prostate, transperineal, ultrasound-guided (ie, sextant, ultrasound-localized discrete lesion[s])
55710	Biopsy, prostate, transperineal, ultrasound-guided (ie, sextant) with MRI-fusion-guidance biopsy, first targeted lesion
55711	Biopsy, prostate, transrectal, MRI-ultrasound-fusion guided, targeted lesion(s) only, first targeted lesion

55712	Biopsy, prostate, transperineal, MRI-ultrasound-fusion guided, targeted lesion(s) only, first targeted lesion
55713	Biopsy, prostate, in-bore CT- or MRI-guided (ie, sextant), with biopsy of additional targeted lesion(s), first targeted lesion
55714	Biopsy, prostate, in-bore CT- or MRI-guided targeted lesion(s) only, first targeted lesion
58150	TOTAL HYSTERECTOMY
58180	PARTIAL HYSTERECTOMY
58200	EXTENSIVE HYSTERECTOMY
58210	EXTENSIVE HYSTERECTOMY
58260	VAGINAL HYSTERECTOMY
58262	VAG HYST INCLUDING T/O
58263	VAGINAL HYSTERECTOMY, FOR UTERUS 250 G OR LESS; WITH REMOVAL OF TUBE(S), AND/OR OVARY(S), WITH REPAIR OF ENTEROCELE
58290	VAG HYST COMPLEX
58291	VAGINAL HYSTERECTOMY, FOR UTERUS GREATER THAN 250 G; WITH REMOVAL OF TUBE(S) AND/OR OVARY(S)
58292	VAG HYST T/O & REPAIR COMPL
58542	LAPAROSCOPY, SURGICAL, SUPRACERVICAL HYSTERECTOMY, FOR UTERUS 250 G OR LESS; WITH REMOVAL OF TUBE(S) AND/OR OVARY(S)
58544	LAPAROSCOPY, SURGICAL, WITH VAGINAL HYSTERECTOMY, FOR UTERUS GREATER THAN 250 G; WITH REMOVAL OF TUBE(S) AND/OR OVARY(S)
58552	LAPAROSCOPY, SURGICAL, WITH VAGINAL HYSTERECTOMY, FOR UTERUS 250 G OR LESS; WITH REMOVAL OF TUBE(S) AND/OR OVARY(S)
58554	LAPAROSCOPY, SURGICAL, WITH VAGINAL HYSTERECTOMY, FOR UTERUS GREATER THAN 250 G; WITH REMOVAL OF TUBE(S) AND/OR OVARY(S)
58570	TLH UTERUS 250 G OR LESS
58571	TLH W/T/O 250 G OR LESS
58573	TLH W/T/O UTERUS OVER 250 G
58578	UNLISTED LAPAROSCOPY PROCEDURE, UTERUS
58579	UNLISTED HYSTEROSCOPY PROCEDURE, UTERUS
58674	LAPS ABLTJ UTERINE FIBROIDS
58679	UNLISTED LAPAROSCOPY PROCEDURE, OVIDUCT, OVARY
58720	SALPINGO-OOPHORECTOMY, COMPLETE OR PARTIAL, UNILATERAL OR BILATERAL (SEPARATE PROCEDURE)
58940	OOPHORECTOMY, PARTIAL OR TOTAL, UNILATERAL OR BILATERAL
64633	DESTROY CERV/THOR FACET JNT
64634	DESTROY C/TH FACET JNT ADDL
64635	DESTROY LUMB/SAC FACET JNT
64636	DESTROY L/S FACET JNT ADDL
64721	CARPAL TUNNEL SURGERY
81378	HLA I & II TYPING HR
81382	HLA II TYPING 1 LOC HR

86832	HLA CLASS I HIGH DEFIN QUAL
86833	HLA CLASS II HIGH DEFIN QUAL
92700	OTORHINOLARYNGOLOGICAL SERVICE OR PROCEDURE
L8603	INJ COLL IMPL URIN TRACT 2.5 ML SYR
L8604	INJ BULKING AGT URINARY TRACT 1 ML
L8605	INJ BLK AGT DX/HA CP IMPL ANAL 1 ML
L8606	INJ SYNTH IMPL URIN TRACT 1 ML SYR
Q5125	INJ, FILGRASTIM-AYOW, BIOSIMILAR, (RELEUKO), 1 MICROGRAM
Q5134	INJ, NATALIZUMAB-SZTN, BIOSIMILAR, (TYRUKO), 1 MG
V5140	BINAURAL BEHIND THE EAR
X3900	SINGLE MODALITY TO ONE AREA – INITIAL 30 MINUTES
X3902	SINGLE MODALITY TO ONE AREA – EACH ADDITIONAL 15 MINUTES
X3904	SINGLE PROCEDURE TO ONE AREA – INITIAL 30 MINUTES
X3906	SINGLE PROCEDURE TO ONE AREA – EACH ADDITIONAL 15 MINUTES
X3908	PHYSICAL THERAPY
X3910	PHYSICAL THERAPY
X3924	PHYSICAL THERAPY PRELIMINARY EVALUATION REHABILITATION CENTER, SNF, ICF
X4300	LANGUAGE EVALUATION
X4301	SPEECH EVALUATION
X4500	SP HR HR DIAG AUDIOLOG EVALUATION
X4501	SP HR HR DIAG AUDIOLOG EVALUATION
X4504	SP HR O HR S AUDIOMETRY DURING SUR

35 codes have had comments added or updated:

CPT Code	Description	Comment
J0897	INJ, DENOSUMAB, 1 MG	Preferred denosumab products are Q5162 (Bildyos/Bilprevda) or Q5167 (Enoby/Xtrenbo) which do not require a PAR.
J1299	INJ ECULIZUMAB 2 MG	Prefered eculizumab products is Q5151 (Epysqli) which does not require a PAR.
J1437	INJ, FERRIC DERISOMALTOSE (MONOFERRIC), 10 MG	Preferred injectable iron products are Q0138 (Feraheme), J2916 (Ferrlecit), J1750 (Infed), and J1756 (Venofer) which do not require a PAR.
J1439	INJ, FERRIC CARBOXYMALTOSE (INJECTAFER), 1 MG	Preferred injectable iron products are Q0138 (Feraheme), J2916 (Ferrlecit), J1750 (Infed), and J1756 (Venofer) which do not require a PAR.
J1442	INJ FILGRASTIM, EXCL BIOSIMLARS, 1 MICROGRAM	Preferred filgrastim products are Q5101 (Zarxio), Q5110 (Nivestym), Q5125 (Relueko), and J1447 (Granix) which do not require a PAR.

J1745	INJ INFLIXIMAB EXCL BIOSIMILR 10 MG	Preferred infliximab products are Q5121 (Avsola) and Q5103 (Inflectra) which do not require a PAR.
J1748	INJ ZYMFENTRA 10 MG	Preferred infliximab products are Q5121 (Avsola) and Q5103 (Inflectra) which do not require a PAR.
J3357	INJ, USTEKINUMAB SUB CU, 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.
J3358	INJ, USTEKINUMAB IV, 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.
J9035	INJECTION BEVACIZUMAB 10 MG	Claims for >2 units per DOS require a prior authorization. Claims for ≤2 units per DOS do not require a prior authorization. Preferred bevacizumab products are Q5107 (Mvasi) and Q5118 (Zirabev) which do not require a PAR.
J9312	INJECTION RITUXIMAB 10 MG	Preferred rituximab products are Q5123 (Riabni), Q5119 (Ruxience), and Q5115 (Truxima) which do not require a PAR for members 18 years of age and older.
J9355	INJ, TRASTUZUMAB EXCLD BIOSIMILARS, 10 MG	Preferred trastuzumab products are Q5112 (Ontruzant) and Q5116 (Trazimera) which do not require a PAR.
Q5104	INJ INFLIXIMAB-ABDA BIOSIMILR 10 MG	Preferred infliximab products are Q5121 (Avsola) and Q5103 (Inflectra) which do not require a PAR.
Q5111	INJ, PEGFILGRASTIM-CBQV (UDENYCA), BIOSIMILAR, 0.5 MG	Preferred pegfilgrastim products are J2506 (Neulasta), Q5108 (Fulphila), and Q5120 (Ziextenzo) which do not required a PAR.
Q5113	INJ, TRASTUZUMAB-PKRB (HERZUMA), BIOSIMILAR, 10 MG	Preferred trastuzumab products are Q5112 (Ontruzant) and Q5116 (Trazimera) which do not require a PAR.
Q5114	INJ, TRASTUZUMAB-DKST (OGIVRI), BIOSIMILAR, 10 MG	Preferred trastuzumab products are Q5112 (Ontruzant) and Q5116 (Trazimera) which do not require a PAR.
Q5115	INJ, RITUXIMAB-ABBS, BIOSIMILAR, (TRUXIMA), 10 MG	PA required for patients under 18 years of age; not required for patients 18 years of age and older
Q5117	INJ, TRASTUZUMAB-ANNS (KANJINTI), BIOSIMILAR, 10 MG	Preferred trastuzumab products are Q5112 (Ontruzant) and Q5116 (Trazimera) which do not require a PAR.

Q5122	IN, PEGFILGRASTIM-APGF (NYVEPRIA), BIOSIMILAR, 0.5 MG	Preferred pegfilgrastim products are J2506 (Neulasta), Q5108 (Fulphila), and Q5120 (Ziextenzo) which do not required a PAR.
Q5123	INJ, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI), 10 MG	PA required for patients under 18 years of age; not required for patients 18 years of age and older
Q5126	INJ BEVACIZUMAB-MALY (ALYMSYS), BIOSIMILAR, 10 MG	Preferred bevacizumab products are Q5107 (Mvasi) and Q5118 (Zirabev) which do not require a PAR.
Q5127	INJ, PEGFILGRASTIM-FPGK (STIMUFEND), BIOSIMILAR, 05 MG	Preferred pegfilgrastim products are J2506 (Neulasta), Q5108 (Fulphila), and Q5120 (Ziextenzo) which do not required a PAR.
Q5129	INJ BEVACIZUMAB-ADCD (VEGZELMA), BIOSIMILAR, 10 MG	Preferred bevacizumab products are Q5107 (Mvasi) and Q5118 (Zirabev) which do not require a PAR.
Q5130	INJ, PEGFILGRASTIM-PBBK (FYLNETRA), BIOSIMILAR, 0.5 MG	Preferred pegfilgrastim products are J2506 (Neulasta), Q5108 (Fulphila), and Q5120 (Ziextenzo) which do not required a PAR.
Q5136	INJ, DENOSUMAB-BBDZ, BIOSIMILAR, (JUBBONTI/WYOST), 1 MG	Preferred denosumab products are Q5162 (Bildyos/Bilprevda) or Q5167 (Enoby/Xtrenbo) which do not require a PAR.
Q5137	INJ, USTEKINUMAB-AUUB (WEZLANA), SUB CU, 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.
Q5138	INJ, USTEKINUMAB-AUUB (WEZLANA), IV, 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.
Q5146	INJ, TRASTUZUMAB-STRF (HERCESSI), BIOSIMILAR, 10 MG	Preferred trastuzumab products are Q5112 (Ontruzant) and Q5116 (Trazimera) which do not require a PAR.
Q5152	INJ, ECULIZUMAB-AEEB (BKEMV), 2 MG	Prefered eculizumab products is Q5151 (Epysqli) which does not require a PAR.
Q5155	Aflibercept-yszy (Yesafili)	
Q5157	INJ, DENOSUMAB-BMWO, BIOSIMILAR (STOBLOCO, OSENVELT), 1 MG	Preferred denosumab products are Q5162 (Bildyos/Bilprevda) or Q5167 (Enoby/Xtrenbo) which do not require a PAR.
Q5158	INJ, DENOSUMAB-BNHT, BIOSIMILAR (BOMYNTRA, CONEXXENCE), 1 MG	Preferred denosumab products are Q5162 (Bildyos/Bilprevda) or Q5167

		(Enoby/Xtrenbo) which do not require a PAR.
Q9996	INJ, USTEKINUMAB-TTWE (PYZCHIVA), SUB CU, 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.
Q9998	INJ, USTEKINUMAB-AEKN (SELARSDI), 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.
Q9999	INJ, USTEKINUMAB-AAUZ (OTULFI), 1 MG	Preferred ustekinumab products are Q5099 (Steqeyma) and Q5167 (Starjemza) which do not require a PAR.

For questions, contact the HPSM Provider Services department at **PSInquiries@hpsm.org**.

Thank you,
The Health Plan of San Mateo